Company Overview

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, manufacturing, and commercialization of generic oral dosage form medications, with an emphasis on controlled‑release and abuse‑deterrent technologies. The company operates within the U.S. generic pharmaceuticals industry, primarily serving prescription drug markets that include central nervous system (CNS) therapies, pain management, and attention deficit hyperactivity disorder (ADHD). Its revenue is driven largely by the sale of FDA‑approved generic drugs through wholesale and distribution channels in the United States.

The company’s strategic positioning centers on proprietary formulation technologies designed to address complex generics that face higher regulatory and technical barriers to entry. Founded in the late 1990s, Elite Pharmaceuticals evolved from a development‑stage company into a vertically integrated manufacturer following the expansion of its New Jersey‑based manufacturing facility and the receipt of multiple FDA approvals. Over time, the company transitioned its focus toward higher‑value generics, particularly controlled substances, to differentiate itself within a highly competitive market.

Business Operations

Elite Pharmaceuticals operates primarily through a single reportable business segment focused on pharmaceutical product development and manufacturing. Its core operations include drug formulation, clinical and bioequivalence studies, regulatory submissions, and commercial‑scale manufacturing. The company generates revenue from the sale of its generic pharmaceutical products, which are distributed through national wholesalers, regional distributors, and select marketing partners in the United States.

The company conducts manufacturing and packaging through its wholly owned subsidiary, Elite Pharmaceuticals Manufacturing, Inc., which operates an FDA‑registered facility. Operations are predominantly domestic, with no material direct manufacturing operations outside the United States. Elite controls proprietary controlled‑release and abuse‑deterrent formulation technologies used across multiple approved and pipeline products, supporting both internal commercialization and partnered product launches.

Strategic Position & Investments

Elite Pharmaceuticals’ strategic direction emphasizes expanding its portfolio of complex generics, particularly products with controlled‑release profiles and abuse‑deterrent characteristics that are more difficult for competitors to replicate. Growth initiatives include pursuing additional FDA approvals for internally developed products, lifecycle management of existing products, and selective in‑licensing arrangements to broaden its commercial portfolio.

The company has historically invested in manufacturing infrastructure, formulation research, and regulatory capabilities rather than large‑scale acquisitions. Its strategy prioritizes organic growth supported by its manufacturing subsidiary and targeted collaborations for distribution and marketing. Emerging focus areas include reformulated legacy drugs and niche controlled substances where regulatory complexity provides competitive insulation.

Geographic Footprint

Elite Pharmaceuticals’ operations are concentrated in the United States, where it maintains its corporate headquarters and primary manufacturing facilities in New Jersey. The company’s commercial activities are almost entirely domestic, reflecting its focus on the U.S. prescription drug market and FDA‑regulated products.

While Elite does not maintain significant international manufacturing operations, its products may indirectly reach non‑U.S. markets through distribution partners. The company’s geographic influence remains primarily North American, with strategic emphasis on nationwide U.S. market penetration rather than global expansion.

Leadership & Governance

Elite Pharmaceuticals was founded under the leadership of industry veterans with experience in pharmaceutical development and manufacturing. The company is led by an executive team that emphasizes disciplined capital allocation, regulatory execution, and focus on technically complex generics as a long‑term strategic vision.

Key members of the leadership team include:

• Eli Weiss – Chairman of the Board and Chief Executive Officer
• Jeffrey Levy – Chief Financial Officer
• Prashant Patel – Executive Vice President, Operations

The leadership philosophy centers on leveraging in‑house technical expertise and manufacturing control to compete in specialized segments of the generic pharmaceutical market while maintaining regulatory compliance and cost discipline.